Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination. by Du, T et al.
  1
Bifunctional CD4-DC-SIGN Fusion Proteins Demonstrate Enhanced 1 
Avidity to gp120 and Inhibit HIV-1 Infection and Dissemination 2 
 3 
Tao Du1,2, Kai Hu1,2, Jun Yang1†, Jing Jin3, Chang Li1,2, Daniel Stieh4, George E. 4 
Griffin4, Robin J. Shattock5, Qinxue Hu1,4* 5 
 6 
Running title: CLDs inhibit HIV infection and dissemination 7 
 8 
1State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of 9 
Sciences, Wuhan 430071, China 10 
2Graduate University, Chinese Academy of Sciences, Beijing 100049, China 11 
3Department of Obstetrics and Gynecology, Hubei Hospital of Traditional Chinese 12 
Medicine, Wuhan 430061, China 13 
4Center for Infection and Immunity, St George’s University of London, London, 14 
SW17 0RE, UK 15 
5Section of Infectious Diseases, Faculty of Medicine, Imperial College London, St. 16 
Mary's Campus, London W2 1PG, UK 17 
 18 
*Corresponding author. Mailing address: State Key Laboratory of Virology, Wuhan 19 
Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.  20 
Phone: +86 27 8719 9992. Fax: +86 27 8719 9992. Email: qhu@wh.iov.cn 21 
†Current address: Zhengzhou Tobacco Research Institute, Zhengzhou 450001, China. 22 
 23 
Abstract: 248 words. Text: 4826 words. 2 tables + 3 figures. 24 
Supplementary material: 2 tables + 4 figures 25 
 Copyright © 2012, American Society for Microbiology. All Rights Reserved.
Antimicrob. Agents Chemother. doi:10.1128/AAC.00623-12 
AAC Accepts, published online ahead of print on 11 June 2012
 o
n
 M
ay 24, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  2
ABSTRACT 26 
Early stages of mucosal infection are potential targets for HIV-1 prevention. CD4 is 27 
the primary receptor in HIV-1 infection while DC-SIGN likely plays an important role 28 
in HIV-1 dissemination in particular during sexual transmission. To test the hypothesis 29 
that an inhibitor simultaneously targeting both CD4 and DC-SIGN binding sites on 30 
gp120 may provide a potent anti-HIV strategy, we designed constructs by fusing the 31 
extracellular CD4 and DC-SIGN domains together with varied arrangements of the 32 
lengths of CD4, DC-SIGN and the linker. We expressed, purified and characterized a 33 
series of soluble CD4-linker-DC-SIGN (CLD) fusion proteins. Several CLDs, 34 
composed of a longer linker and an extra neck domain of DC-SIGN, had enhanced 35 
affinity for gp120 as evidenced by molecular interaction analysis. Furthermore, such 36 
CLDs exhibited significantly enhanced neutralization activity against both laboratory-37 
adapted and primary HIV-1 isolates. Moreover, CLDs efficiently inhibited HIV-1 38 
infection in trans via a DC-SIGN expressing cell line and primary human dendritic 39 
cells.  This was further strengthened by the results from the human cervical explant 40 
model, showing that CLDs potently prevented both localized and disseminated 41 
infections. This is the first time that sDC-SIGN-based bifunctional proteins have 42 
demonstrated anti-HIV potency. Our study provides proof-of-concept that targeting 43 
both CD4 and DC-SIGN binding sites on gp120 represents a novel antiviral strategy. 44 
Given that DC-SIGN binding to gp120 increases exposure of the CD4 binding site 45 
and that the soluble forms of CD4 and DC-SIGN occur in vivo, further improvement 46 
of CLDs may render their potential to be used as prophylaxis or therapeutics. 47 
48 
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INTRODUCTION  49 
The majority of HIV-1 infections are acquired by mucosal exposure, with sexual 50 
transmission as the leading mode of HIV-1 infection worldwide. The distribution of 51 
dendritic cells (DCs) in cervicovagina and colorectum may allow them to be one of 52 
the first cell types to contact HIV-1 (21, 34, 57). DCs may capture HIV-1 by 53 
attachment receptors in particular DC-SIGN and transfer the virus to permissive CD4+ 54 
T cells, resulting in trans-infection (11, 19, 37, 55). In addition, DC-SIGN binding to 55 
HIV-1 increases local concentration of virus on DC surface and can enhance cis-56 
infection via the low levels of CD4 and CCR5 on DCs (38).  Both HIV-1-captured and 57 
-infected DCs can efficiently release virus particles to CD4+ T cells at the points of 58 
cell contact termed virological synapses (41). Evidences from colorectal explant study 59 
indicate that DC-SIGN accounts for 90% of HIV-1 binding on mucosal mononuclear 60 
cells (23).  Our previous study using a cervicovaginal model demonstrates that 61 
simultaneous blockade of CD4 and mannose-binding C-type lectin receptors (MCLRs) 62 
including DC-SIGN is required to inhibit HIV-1 uptake and dissemination by 63 
migratory cells (28). Given their critical roles likely played in HIV-1 transmission, 64 
CD4 and DC-SIGN are important targets for the development of topical microbicides. 65 
 66 
HIV-1 entry and transmission involves complex interaction between viral envelope 67 
glycoprotein (Env) and receptors on host cells. The binding of gp120 to CD4 is 68 
virtually universal among HIV-1 isolates. Soluble CD4 (sCD4), which acts as a 69 
receptor decoy to prevent the engagement of HIV-1 Env with cell surface CD4, 70 
represents a promising competitive viral attachment inhibitor. However, despite its 71 
efficient neutralization activity against laboratory-adapted HIV-1 strains, sCD4 72 
showed poor antiviral activity against primary HIV-1 isolates and very large doses of 73 
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sCD4 were required to achieve modest reductions of viral loads in vivo (33). This is 74 
likely due to the relatively lower Env-binding affinity of sCD4 per se compared with 75 
that of target cell-bound CD4 (52). Although PRO-542 (CD4-IgG2), a tetrameric 76 
fusion protein between CD4 and immunoglobulin-G, is much more potent in vitro 77 
than the parental monomer, the translation of this improvement to clinical use remains 78 
uncertain (2, 51). The interaction of HIV-1 with DC-SIGN does not result in direct 79 
infection of DCs, but instead enhances cis- or/and trans-infection. Several studies 80 
have shown that antagonists against DC-SIGN inhibit DC-SIGN-mediated HIV-1 81 
transmission (7, 42, 46), whereas the antiviral activity of sDC-SIGN seems more 82 
complex (25, 40). Although sDC-SIGN decreases the capture of HIV-1 by DC-SIGN 83 
(39), sDC-SIGN binding to HIV-1 Env can also increase the exposure of the CD4 84 
binding site on gp120 which in turn contributes to enhancement of infection (25), 85 
compromising the development of DC-SIGN as a single agent.  86 
 87 
We hypothesized that an inhibitor against both CD4 and DC-SIGN binding sites on 88 
gp120 might represent a better anti-HIV strategy and that a sCD4-DC-SIGN fusion 89 
protein could have potent antiviral activity. As a fusion protein, the binding of sDC-90 
SIGN to Env may not only enhance the engagement of sCD4 to gp120, but also block 91 
the DC-SIGN binding sites on gp120 to prevent HIV-1 transmission.  In the current 92 
study, we designed, expressed, purified and characterized a series of soluble CD4-93 
linker-DC-SIGN (CLD) fusion proteins. We assessed the protein oligomeric state and 94 
gp120 binding affinity of CLDs, and tested their anti-HIV activity against several 95 
laboratory-adapted and primary isolates in cis-infection of target cells. We further 96 
examined the anti-HIV potency in trans-infection of target cells using DC-SIGN-97 
expressing cell line and primary dendritic cells. The capability in inhibiting HIV-1 98 
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infection and dissemination was also evaluated in a human cervical explant model. 99 
Our findings demonstrate that several CLDs had significantly enhanced avidity to 100 
gp120 and much improved anti-HIV activity and could potently prevent both 101 
localized and disseminated infections of HIV-1. Our study proves a concept that 102 
targeting both CD4 and DC-SIGN binding sites on gp120 represents a novel antiviral 103 
strategy, and may have implications for the development of CD4/DC-SIGN based 104 
therapeutic and prophylactic antiretrovirals. 105 
106 
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MATERIALS AND METHODS  107 
Plasmids, cell lines, viruses and proteins.   108 
env clones BaL, MWS2 and CH811 in pcDNA3.1, and viruses HIV-1BaL and HIV-1RF 109 
were described previously (29, 31, 32). U87-CD4.CCR5 cell line and pNL4-110 
3.Luc.R−E− were obtained from NIH AIDS Research and Reference Reagent Program, 111 
Division of AIDS, NIH. 293T cell line was purchased from the American Type 112 
Culture Collection. Vector pET28a(+) was from Novagen. Raji/DC-SIGN cell line, 113 
and anti-DC-SIGN antibodies mAb507 and mAb 526 were described previously (28, 114 
34). Anti-CD4 mAb RPA-T4 was from BD Biosciences. Mannan was from Sigma-115 
Aldrich. Protein CN54 gp140 was described previously (32).  116 
 117 
Design and genetic engineering of expression constructs 118 
The CD4 and DC-SIGN DNA sequences were amplified from human CD4 gene in 119 
pcDNA3.1 (31) and human DC-SIGN gene in pcDNA3.1 (39), respectively. PCR 120 
primers used in this study were listed in Table S1. Amplified DNA fragments were 121 
subsequently cloned into pET28a(+) after corresponding enzyme digestion. All 122 
recombinant DNA clones were confirmed by sequencing. 123 
 124 
Protein expression and purification 125 
E.coli strain Rosetta (Novagen) was used for protein expression as described 126 
previously (39). After induction with isopropyl-β-D-thiogalactoside for 4 h, the 127 
bacteria were collected and lysed by ultrasonic treatment. The insoluble fraction in the 128 
lysates was washed twice with PBS supplemented with 1M GuHCl, and resuspended 129 
in denaturation buffer (10 mM Tris, 500mM NaCl, 6M GuHCl, 5 mM DTT, pH8.0). 130 
The denatured recombinant proteins were refolded for 24 h at 4°C in refolding buffer 131 
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(10 mM Tris, 500 mM NaCl, 3 mM CaCl2, 10% glycerol, 3mM GSH, 0.3mM GSSG, 132 
pH8.0)(14, 53). After refolding, the solutions were loaded onto a pre-equilibrated 133 
nickel-charged chelating Sepharose Fast Flow column (GE healthcare). Proteins were 134 
purified according to the manufacturer’s instructions. 135 
 136 
SDS-PAGE and western blotting 137 
Purified recombinant CLDs were resolved by 12% SDS-PAGE and transferred onto a 138 
PVDF membrane (Millipore) using the Microarray System (Bio-Rad). After being 139 
blocked in PBS plus 4% non-fat milk at 4°C overnight, the membrane was washed 140 
with TBS-T and subsequently incubated with anti-DC-SIGN mAb for 2 h at room 141 
temperature. After washes with TBS-T, the membrane was incubated with HRP-142 
conjugated goat anti-mouse antibody for 2 h at room temperature. Luminometric 143 
detection of target proteins was achieved with SuperSignal West Dura 144 
Chemiluminescent Substrate (Pierce, Thermo Scientific) and visualized by a CCD 145 
camera imager (Alpha Innotech). 146 
 147 
Analytical ultracentrifugation 148 
Analytic ultracentrifugation was performed at 20°C using a Beckman Optima XL-I 149 
analytical ultracentrifuge equipped with an An-60Ti rotor. Purified recombinant 150 
proteins in dialysis buffer (10 mM Tris–HCl, pH 7.4, 200mM NaCl, 5 mM CaCl2 and 151 
0.1mM Glutathione) were loaded into 12mm path-length cells and centrifuged at 152 
50,000 rpm for sCD4 and sDC-SIGN, and 40,000rpm for C35NDs60cc. A total of 200 153 
absorbance scans (280nm) were recorded and data were analyzed with a C(s) 154 
distribution of the Lamm equation solutions calculated by the SEDFIT program 155 
(www.analyticalultracentrifugation.com/download.htm) (16, 47). Protein partial 156 
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specific volume values, solution density and solution viscosity were calculated with 157 
SEDNTERP (http://www.jphilo.mailway.com/download.htm).    158 
 159 
Binding kinetics analysis  160 
The buffer of tested protein was exchanged into phosphate buffered saline (pH7.4) 161 
with a desalt spin columns (Thermo Scientific). CN54 gp140 was biotinylated by 162 
mixing with Sulfo-NHS-LC-Biotinylation reagents in PBS for 30 min at room 163 
temperature according to the manufacturer's instructions (Pierce). The interactions 164 
between gp140 and CLDs were measured on a Forte-Bio Octet Red System (ForteBio) 165 
(1). This system monitors interference of light reflected from the surface of sensor to 166 
measure the thickness of molecules bound to the sensor surface. The biotinylized 167 
gp140 (5 μg/ml) was immobilized on streptavidin biosensors. After reaching baseline, 168 
sensors were dipped into different concentrations of tested proteins for association, 169 
and then moved into running buffer (3mM CaCl2, 0.1% BSA, and 0.05% Tween20 in 170 
PBS, pH7.4) for dissociation. A buffer-only reference was subtracted from all curves. 171 
Octet Molecular Interaction System software was used for data analysis. 172 
 173 
Binding in the presence of antibodies against CD4 or/and DC-SIGN was also 174 
performed. C35NDs60c was immobilized on anti-his biosensor. In the first association 175 
phase, sensors were incubated in running buffer (20mM Tris, 150mM NaCl, 3mM 176 
CaCl2, 0.1% BSA, and 0.05% Tween20, pH8.0) supplemented with mAbs against 177 
CD4 (20μg/ml RPA-T4) or/and DC-SIGN (507 + 526; 20μg/ml each ) as association 178 
buffer for 1800 seconds. Association was keep performing in the presence or absence 179 
of 5 μg/ml CN54 gp140 for another 1800 seconds. Dissociation was subsequently 180 
performed in running buffer for 1800 seconds. 181 
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 182 
Measurement of cytotoxicity 183 
Cytotoxicity of fusion proteins was determined by MTT assay as described previously 184 
(30). TZM-bl cells were seeded in 96-well plates overnight and subsequently cultured 185 
in medium containing serially diluted proteins for 3 d. Medium was then removed and 186 
100 μl of MTT solution (medium containing 0.5mg/ml 3-(4, 5-dimethylthiazol-2-yl)-187 
2,5-diphenyltetrazolium bromide) was added to each well and incubated for 4 h at 188 
37°C.  After removal of MTT solution, 100 μl of acid-isopropanol (0.04N HCl in 189 
isopropanol) was added and the optical density was read with a Modulus Microplate 190 
Luminometer (Turner BioSystems). 191 
 192 
Infection 193 
Stocks of pseudotyped reporter viruses were prepared by co-transfecting 293T cells 194 
with Env expression constructs and plasmid pNL4-3.Luc.R-E-  as described previously 195 
(32). U87-CD4.CCR5 or TZM-b1 cells (1×104 cells/ well) were seeded in 96-well 196 
plates 1 d prior to infection. Env-pseudotyped viruses, HIV-1BaL or HIV-1RF were 197 
incubated with serially diluted CLDs for 1 h at 37°C and then the mixtures containing 198 
viruses and the proteins were added to the pre-seeded cells. The luciferase activity of 199 
cell lysate was determined 48 h post-infection with a Modulus Microplate 200 
Luminometer (Turner BioSystems). IC50 and IC90 values were calculated using 201 
Prism 4.1 (GraphPad).  202 
 203 
Virus capture and transfer assay 204 
HIV-1 was preincubated with CLDs at 37°C for 1 h in round bottom 96-well plates, 205 
while Raji/DC-SIGN cells (1.5×105 cells/ well) were pretreated with 1 mg/ml mannan. 206 
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Following incubation, Raji/DC-SIGN cells were added into CLD-pretreated HIV-1 207 
while the same amount of HIV-1 was added to mannan-pretreated Raji/DC-SIGN 208 
cells. Following incubation at 37°C for another 2 h, unbound viruses were extensively 209 
washed with PBS. For HIV-1 capture assay, washed Raji/DC-SIGN cells were lysed 210 
directly and p24 was measured as described previously (27, 28). For virus transfer 211 
assay, washed Raji/DC-SIGN cells were then co-cultured with U87-CD4.CCR5 cells. 212 
48 h later, cells were lysed and luciferase activity was determined. 213 
 214 
Human monocyte-derived DCs (MDDCs) were generated from a highly enriched 215 
population of CD14+ monocytes. Briefly, PBMCs were isolated using a Ficoll-216 
Hypaque density gradient followed by negative selection using the Monocyte 217 
Isolation Kit according to the manufacturer's protocol (Miltenyi Biotec). To obtain 218 
immature MDDCs (iMDDCs), monocytes were cultured in the presence of IL-4 (500 219 
U/ml; R&D Systems) and GM-CSF (800 U/ml; R&D Systems) for 7 d (3, 28).  220 
iMMDCs were used for HIV-1 capture and transfer assay as described above.  221 
 222 
Culture and infection of human cervical tissues 223 
Cervical tissues were obtained from women undergoing planned therapeutic 224 
hysterectomy in the absence of any cervical pathology at Hubei Hospital of 225 
Traditional Chinese Medicine or St George’s Hospital London, with written consent 226 
obtained from all tissue donors according to the Local Research Ethics Committee. In 227 
brief, 3mm× 3mm explants were cultured in 200 μl of supplemented RPMI 1640 (28). 228 
Explants were pre-incubated in the presence or absence of C15D or antibody against 229 
CD4 or DC-SIGN for 1 h at 37°C. In dose-response experiments, explants were pre-230 
incubated in the presence of serially diluted C35NDs60c, sCD4 or sDC-SIGN. After a 231 
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2-h exposure to HIV-1BaL at 37°C, cervical explants were extensively washed to 232 
remove unbound viruses and inhibitors, and then cultured for 9 d at 37°C in fresh 233 
plates. For migratory cell experiments, after exposure to viruses, explants were 234 
cultured in the presence of 100 ng/ml recombinant human MIP-3β (R&D Systems) 235 
for 24 h at 37°C. Cells emigrating out of the explants were washed and co-cultured 236 
with PM1 cells （ 0.5×105 cells/well in 96-well plate) at 37°C. In all cases, 237 
supernatants were collected and stored at -80°C before subsequent measurement of 238 
p24 by ELISA (28). 239 
  240 
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RESULTS   241 
Design and construction of plasmids expressing recombinant CD4-linker-DC-242 
SIGN (CLD) fusion proteins 243 
The CD4 binding site lies on gp120 neutralizing domain, while DC-SIGN recognizes 244 
mannose type glycans distributed around the outer domain (22, 45). Due to the 245 
distance between CD4 and DC-SIGN binding sites on gp120, an optimal linker is 246 
required to ensure that both components of the fusion protein can access their binding 247 
sites. Based on that Gly4Ser repeat has been broadly used in the construction of fusion 248 
proteins, in the current study, 3, 4, 5 and 7 Gly4Ser repeat linkers, and linkers of 5 and 249 
7 Gly4Ser repeats integrated with DC-SIGN neck domain, were designed (Table S1 250 
and S2). Since CD4 D1D2 domains affect the binding activity to gp120, while gp120-251 
binding residues are all located within the first N-terminal domain (D1) of CD4 (13), 252 
we designed CD4-linker-DC-SIGN fusion proteins containing CD4 D1D2 domains, 253 
or the first 87aa or 106aa of CD4 D1 domain. In addition, modifications were made 254 
on C35D construct by truncating CD4 moiety (mC35D and sC35D contained the first 255 
108aa and 87aa of CD4 D1, respectively) or adding DC-SIGN neck domain (C25ND 256 
and C35ND). A Ser to Cys mutation at aa 60, which can form a disulfide bond with 257 
gp120 (8), was introduced into C35ND, designated as C35NDs60c (Fig. 1a). 258 
 259 
We generated nine pET28a constructs encoding the following recombinant fusion 260 
proteins: C15D, C20D, C25D, C35D, mC35D, sC35D, C25ND, C35ND and 261 
C35NDs60c. Two pET28a plasmids expressing sCD4 and sDC-SIGN, respectively, 262 
were also constructed (Table S1 and Table S2). The schematic diagrams of the 263 
constructs are illustrated in Fig. 1a and 1b.  264 
 265 
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Expression, refolding, purification and characterization of CLDs 266 
The fusion proteins produced in E.coli Rosetta existed mainly as inclusion bodies.  267 
Modulating factors which impact protein expression, such as host bacterial strain, 268 
IPTG concentration and inducing temperature, had little effect on the solubility of 269 
CLDs. In order to obtain soluble proteins, protein refolding was performed by slowly 270 
adding the denatured recombinant proteins into the refolding buffer. Final 271 
concentration was kept at 30-50 μg/ml to avoid protein aggregation and precipitation. 272 
All recombinant proteins in this study contained his-tag at N terminus. The refolded 273 
proteins were purified with Ni-Resin column and target proteins were eluted with 274 
buffer containing 300 mM imidazole. Imidazole-free proteins were obtained by 275 
dialysis twice at 4°C.  276 
 277 
An example of the purified fusion proteins, C35NDs60c, was analyzed by SDS-PAGE 278 
and western blotting (Fig. 1c). Reducing SDS-PAGE (Fig. 1c, lane 2) and western blot 279 
analysis revealed that C35NDs60c was correctly purified, with an expected band 280 
around 60 KD. C35NDs60c migrated mainly as a single band in both non-reducing 281 
and reducing SDS-PAGE (Fig.1c, lane 2, 3). CD4, a moiety of  the fusion protein, has 282 
three oxidized isoforms, representing reduced protein (R) and the predominant 283 
disulfide-bonded CD4 isoforms (O1/O2) (8), while only O1 is in functional state. 284 
C35NDs60c electrophoresed slightly faster in non-reducing SDS-PAGE than in 285 
reducing SDS-PAGE, indicating that it was in an O1 state containing correct disulfide 286 
bonds. 287 
 288 
Oligomeric state of recombinant CLDs 289 
The function of recombinant fusion proteins can be impacted by their oligomeric state. 290 
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Analytic ultracentrifugation (AUC) was conducted to evaluate the molecular mass of 291 
the proteins. The distributions C(s) of protein sedimentation coefficients are shown in 292 
Fig. 1d. The predicted monomer molecular masses of sDC-SIGN, sCD4 and 293 
C35NDs60c were 18.4 KD, 22.1 KD and 60.5 KD, respectively. sDC-SIGN had a 294 
main peak at 2.0s, corresponding to apparent molecular mass of 22.4 KD. sCD4 295 
showed a major peak around 1.9S, corresponding to apparent molecular mass of 21.5 296 
KD.  sCD4 also had a minor peak with molecular mass of 57.4 KD, but reducing 297 
SDS-PAGE confirmed that sCD4 had no band around 57.4 KD (data not shown).  The 298 
minor peak in the C(s) distribution of sCD4 might be dimers caused by incorrectly 299 
formed disulfide bonds. C35NDs60c demonstrated a major peak at 6.3S, 300 
corresponding to apparent molecular mass of 214.8 KD and a minor peak 9.2S, 301 
corresponding to apparent molecular mass of 398.2KD. In non-reducing SDS-PAGE, 302 
C35NDs60c showed mainly as monomers (60.5 KD) (Fig. 1b, lane 3), although 303 
oligomers were detected, some of which likely formed in non-reducing conditions (8). 304 
The 214.8KD complex in AUC indicated that C35NDs60c existed mainly as tetramers. 305 
This tetramer formation might be contributed by the neck domain of DC-SIGN (49). 306 
C35NDs60c could also form higher oligomer during refolding procedure caused by 307 
incorrectly formed disulfide bonds, which explained the existence of the minor peak. 308 
Taken together, the AUC results showed that D1D2 domain of CD4 and carbohydrate-309 
recognition domain of DC-SIGN existed mainly in monomer form while the majority 310 
of C35NDs60c were tetramers. 311 
 312 
CLDs demonstrate enhanced binding affinity to gp120 313 
We performed direct binding analysis on a Forte-Bio Octet Red System. Streptavidin 314 
biosensor immobilized with biotinylated CN54 gp140 was immersed in different 315 
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concentrations of CLDs (all protein molar concentrations were calculated based on 316 
monomer). To characterize protein interactions, two protein binding models: langmuir 317 
1:1 model and bivalent model were applied (Fig. S1). χ2 was the sum of squared 318 
deviations, where deviation was the difference between the actual data-point and the 319 
fitted curve. Values close to zero indicated a good curve fit (5). As calculated χ2 320 
shown in Table 1, CLDs fitted preferably to the bivalent binding model, whereas the 321 
control proteins sCD4 and sDC-SIGN fitted with the langmuir binding model. These 322 
results demonstrated that, unlike sCD4 and sDC-SIGN, CLDs interacted with gp140 323 
in a bivalent manner, indicating that both CD4 and DC-SIGN moieties of CLDs could 324 
effectively reach their respective binding sites on gp140, either simultaneously or 325 
sequentially. Moreover, as shown in Table 1, the affinity of CLDs with a 35aa linker 326 
to gp140 were obviously higher than that of sCD4 (KD= 1.21E-09 M) and sDC-SIGN 327 
(KD=1.43E-08 M). The difference of affinity between CLDs with 35aa linker and 328 
C15D implied that the length of linkers impacted the interactions between CLDs and 329 
gp120. Linkers in appropriate length benefitted the binding of CLD moieties to gp120, 330 
while short linkers hindered such interactions. Linker with 35aa seemed long enough 331 
to allow effective bindings of the fusion proteins to gp140. Other modifications on 332 
CLDs, such as adding DC-SIGN neck domain or/and introducing Cys to Ser mutation 333 
into CD4, also enhanced the affinity of CLDs to gp140. Compared with the off rate of 334 
CD4 (Kdis = 6.25E-05 S-1), CLDs with 35aa linker dissociated more slowly, indicating 335 
the formation of more stable complexes with gp140. 336 
 337 
When CD4 or DC-SIGN domain of C35NDs60c was blocked by antibodies, the 338 
binding of gp140 to C35NDs60c-immobilized biosensor decreased, and a 339 
combination of anti-CD4 and anti-DC-SIGN antibodies had an additive effect in 340 
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inhibiting C35NDs60c-gp140 interaction in the association phase (Fig. S2). In the 341 
dissociation phase, gp140-C35NDs60c complex appeared to dissociate more slowly 342 
than the antibody-C35NDs60c complex. The difference at the end of dissociation 343 
phase might be due to a competitive binding of gp140 to C35NDs60c by replacing 344 
anti-CD4 or/and anti-DC-SIGN antibodies (Fig. S2). The binding results together 345 
indicate that gp140 can bind to both CD4 and DC-SIGN domains of C35NDs60c, and 346 
that the avidity between C35NDs60c and gp140 is likely higher than that between 347 
C35NDs60c and the antibodies used in this study. 348 
 349 
CLDs inhibit HIV-1 infection in cis 350 
Because the binding of gp120 to CD4 is virtually universal among HIV-1 isolates, 351 
regardless of viral tropism, we expected that CLDs would be active against both R5 352 
and X4 strains. We initially tested the antiviral potency of C15D against HIV-1BaL (R5) 353 
and HIV-1RF (X4) in TZM-bl cells. The IC50s were 60.5 nM and 77.8 nM, 354 
respectively (Table 2.), indicating that CLDs can neutralize HIV-1 regardless of viral 355 
tropism. Subsequent experiments were carried out by using BaL Env-pseudotyped 356 
HIV-1 to infect U87-CD4.CCR5 cells. All CLDs demonstrated anti-HIV activity 357 
(Table 2). Compared with sCD4 (IC50=25.3 nM), C35D showed enhanced 358 
neutralization activity (IC50=15.7 nM), while the CLDs with shorter linkers (C15D, 359 
C20D and C25D) had similar or lower antiviral activity.  It seemed that linker length 360 
was a crucial factor affecting the anti-HIV activity of the CLDs, probably by 361 
interfering with CLD-gp120 interactions. The IC90 of the CLDs had similar trend as 362 
that of IC50.  363 
  364 
CD4-truncated CLDs showed decreased neutralization activity. The IC50s of mC35D 365 
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and sC35D were over 1000nM, at least 40 fold higher than that of C35D.  DC-SIGN 366 
neck domain has seven complete and one incomplete 23-aa long repeats, which forms 367 
helical stretches to aggregate as tetramers.  Adding the neck domain may also 368 
lengthen the linker. The IC50s of C25ND and C35ND were enhanced to 4.9 nM and 369 
5.3 nM, respectively. The similar IC50s of the two fusion proteins imply that a 25aa 370 
linker length is sufficient and the extra l0aa had little effect on the neutralization 371 
activity. The IC50 of C35NDs60c (IC50=3.3 nM) was 1.6 fold lower than that of 372 
C35ND and 7.7 fold lower than that of sCD4. 373 
 374 
As C25ND, C35ND and C35NDs60c exhibited better anti-HIV activity compared to 375 
CLDs with linkers lacking DC-SIGN neck domain, neutralization potency against 376 
primary HIV-1 Envs was further investigated. Two primary HIV-1 Env clones were 377 
used, including MWS2, a clade C Env cloned from semen of a subject known to have 378 
infected women by vaginal intercourse, and CH811, a clade B Env isolated from a 379 
Chinese patient's blood sample. As shown in Table 2, C25ND and C35ND exhibited 380 
much weaker neutralization activity against MWS2 and CH811 than that of HIV-1BaL. 381 
Remarkably, C35NDs60c demonstrated much stronger bioactivity than C25ND and 382 
C35ND, possessing potent neutralization activity against the two primary HIV-1 Envs, 383 
with an IC50 of 13.0 nM and 4.7 nM, respectively. None of the CLDs was cytotoxic 384 
to the tested cells (Table 2). 385 
 386 
Previous studies by others reported that sCD4 or sDC-SIGN at suboptimal 387 
concentrations could enhance HIV-1 infection (25,48,54). We tested whether CLD had 388 
a similar effect. Our results indicated that C35NDs60c did not enhance HIV-1 389 
infection at least in the tested concentration range (Fig. S3a). 390 
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 391 
CLDs inhibit HIV-1 capture and transfer via DC-SING-expressing cells and 392 
iMDDCs 393 
Raji/DC-SIGN cells were used to assess the anti-HIV capability of CLDs against 394 
virus capture and trans-infection. As shown in Fig. 2a and 2b, sCD4 exhibited little 395 
effect in inhibiting HIV-1 capture by DC-SIGN but rendered the bound virus 396 
noninfectious to U87-CD4.CCR5 cells. Interestingly, all CLDs tested at the same 397 
concentration (1000 nM) demonstrated similar trends to sDC-SIGN in interfering with 398 
virus capture by Raji/DC-SIGN cells, as well as similar capacity as sCD4 in inhibiting 399 
virus trans-infection from Raji/DC-SIGN cells to U87-CD4.CCR5 cells.  400 
 401 
To confirm the anti-HIV activity of CLDs in trans-infection, similar experiments were 402 
conducted in iMMDCs. Similar to controls sDC-SIGN and mannan, all CLDs 403 
demonstrated less potency against virus capture than that observed in Raji/DC-SIGN 404 
cells (Fig. 2c). Differences between the DC-SIGN-expressing cell line and iMMDCs 405 
were likely due to differences in receptor repertoire of iMMDCs which also express 406 
other attachment receptors in addition to DC-SIGN. Nevertheless, CLDs still 407 
possessed better efficacy than sCD4 and sDC-SIGN to suppress virus uptake by 408 
iMMDCs (Fig. 2c). Among those, C35NDs60c inhibited more than 50% of HIV-1 409 
capture. Despite the incomplete inhibition of HIV-1 capture, all CLDs showed 410 
enhanced potency against trans-infection, almost completely blocking virus transfer 411 
from iMMDCs to U87-CD4.CCR5 cells (Fig. 2d). These results imply that HIV-1 412 
may binds to iMDDCs via additional attachment receptors other than DC-SIGN, but 413 
CLDs can render the bound virus noninfectious. 414 
 415 
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Considering that saturated concentrations of proteins were used in the above study, we 416 
performed additional dose-response assays. In the neutralization assay, C35NDs60c 417 
was much more potent than a combination of sCD4 and sDC-SIGN (Fig. S3a).  In 418 
viral capture and transfer assays, C35NDs60c also demonstrated better antiviral 419 
activities than sCD4 and sDC-SIGN in combination (Fig. S3b and S3c).   420 
 421 
CLDs inhibit both localized mucosal infection and dissemination pathways  422 
In the absence of a suitable animal model for HIV-1, ex vivo culture of human tissue 423 
explants has been generally accepted as an alternative to mimic in vivo physiological 424 
conditions. We conducted experiments to determine whether CLDs could inhibit HIV-425 
1BaL infection and dissemination in cervical tissues. As a conceptual study, we initially 426 
used C15D to conduct our experiment. Concentrations of all proteins were used at 30 427 
μg/ml(~750 nM for C15D). As seen in Fig. 3a and 3b, anti-CD4 antibody blocked 428 
localized infection, but was incapable of inhibiting virus dissemination in mucosal 429 
tissues. Although antibodies against DC-SIGN might decrease the capture of virus by 430 
migrating cells within mucosa, receptors other than DC-SIGN could play a role in 431 
transmission. A combination of anti-CD4 and anti-DC-SIGN antibodies was required 432 
to block HIV-1BaL infection and dissemination in cervical tissues. Of note, C15D not 433 
only efficiently inhibited localized infection but also prevented disseminated infection 434 
by migratory cells, with better efficacy than the combination of anti-CD4 and anti-435 
DC-SIGN antibodies. In addition, we performed dose-response experiments using 436 
sCD4, sDC-SIGN and an improved CLD (C35NDs60c) against HIV-1BaL infection in 437 
human cervical explants. While sDC-SIGN had little inhibitory effect against HIV-1 438 
infection in the tested concentration range, C35NDs60c demonstrated significantly 439 
enhanced antiviral activity, with an IC50 one log lower than that of  sCD4 (Fig. S4). 440 
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Our data together suggest that further improvement of CLDs may render their 441 
potential to be used as prophylaxis or therapeutics, in particular for microbicide 442 
development. 443 
444 
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DISCUSSION 445 
Effective microbicides need to protect against all potential routes of HIV-1 446 
transmission across mucosal surfaces. Based our previous findings that HIV-1 uptake 447 
and dissemination by migratory dendritic cells (DCs) can occur through CD4 and 448 
mannose binding C-type lectin receptor DC-SIGN (28), in the current study, we 449 
designed, expressed, purified and characterized a series of bi-functional CD4-linker-450 
DC-SIGN fusion proteins (CLDs). We demonstrate that several of the CLDs had 451 
enhanced gp120 binding affinity and much improved antiviral activity against HIV-1 452 
infection and dissemination. 453 
 454 
Soluble CD4 (sCD4) has poor antiviral activity against primary HIV-1 isolates (33). 455 
In order to improve the anti-HIV potency, several strategies have been employed to 456 
date to make fusion proteins, for instance, protein polymerization. Immunoglobulin G 457 
(IgG) is usually used as a frame protein for making fused oligomers. PRO-542, a 458 
tetramer CD4 wherein the Fv portions of both the heavy and light chains of human 459 
IgG2 have been replaced with the D1D2 domains of human CD4, binds to gp120 with 460 
high affinity (2). However, the increased size by fusing to antibody may diminish the 461 
neutralization potency of candidate molecule (10). The large size likely also makes 462 
IgG-anchored fusion protein less able to penetrate into tissues (35). When we 463 
designed and characterized a range of CLDs, we observed that the integration of DC-464 
SIGN neck domain into fusion proteins greatly increased tetramer formation, and 465 
significantly enhanced the antiviral potency against both laboratory-adapted and 466 
primary isolates. This novel polymer strategy could be extended to design other fusion 467 
proteins aiming to enhance bioactivity.   468 
 469 
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Design of sCD4-based fusion proteins simultaneously targeting different binding sites 470 
on gp120 provides another alternative to improve anti-HIV potency. Most fusion 471 
proteins designed to date, including sCD4-17b, m35-sCD4 and CD4HC-(GS7)-IgGE51, 472 
have been focusing on the CD4 binding site and CD4-binding-induced epitopes on 473 
gp120 (9, 36, 56). Different to the molecules described above, CLDs, binding to CD4-474 
binding site and glycans on gp120, were designed to interrupt the interactions between 475 
gp120 and the entry receptor CD4 as well as the attachment receptor DC-SIGN. Such 476 
unique binding mode not only enhanced the engagement of sCD4 to gp120, but also 477 
inhibited the DC-SIGN binding sites on gp120. Although CD4 and DC-SIGN have 478 
little direct interaction, DC-SIGN binding to gp120 causes an allosterically induced 479 
exposure of the CD4 binding site and therefore facilitates a more stable binding of 480 
CD4 to gp120. Indeed, CLDs not only enhanced the neutralization activity, but also 481 
inhibited cis- and trans-infection of HIV-1 in both cellular and human cervical explant 482 
models. Given that there is limited research on sDC-SIGN-based antiretrovirals and 483 
that sDC-SIGN alone is unlikely to be used in practice, our study provides evidence 484 
that DC-SIGN fused to other proteins targeting gp120 may provide an important new 485 
strategy for enhancing anti-HIV potency. As DC-SIGN functions as an attachment 486 
receptor for a range of enveloped viruses such as Dengue, HCV, Ebola and so on (17, 487 
26), the method of fusing DC-SIGN with other functional moieties may be extended 488 
to prevent or treat these additional types of viruses. 489 
 490 
Several CLDs, including C35D, C25ND, C35ND and C35NDs60c, demonstrated 491 
much improved neutralizing activity against HIV-1. In contrast, C15D, C20D and 492 
C25D had similar or decreased antiviral activity compared with that of sCD4. This 493 
implies that fusion proteins expressing two components binding to different sites on 494 
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gp120 per se does not guarantee enhanced bioactivity. The amino acids involved in 495 
CD4 recognition distribute discontinuously around C2, C3 and V5 regions of gp120 496 
(4, 24, 45), whereas DC-SIGN interacts with discontinuously distributed high-497 
mannose oligosaccharides on gp120 (20). Short linkers likely hindered the two 498 
moieties of the fusion proteins from simultaneously interacting with gp120, while a 499 
linker with suitable length could render CLDs higher gp120-binding avidity and better 500 
anti-HIV potency. To this end we did not observe significant difference in terms of 501 
anti-HIV activity when C25ND and C35ND were tested against both laboratory-502 
adapted and primary isolates, including one cloned from semen of a subject known to 503 
have infected women by vaginal intercourse, suggesting that, a linker of 25 amino 504 
acids integrated with an extra DC-SIGN neck domain, may be sufficient for 505 
simultaneous binding of the two moieties to gp120, at least for the isolates tested.  506 
 507 
The signaling pathway activated by binding of HIV-1 to DC-SIGN is thought to cause 508 
immunosuppressive responses and triggers HIV-1 transmission and replication (18). 509 
In addition to masking the CD4-binding site on gp120, CLDs interrupted gp120 510 
glycan-DC-SIGN interaction and inhibited the uptake of virus by host cells, avoiding 511 
potential triggering of the downstream signaling pathways. Several carbohydrate-512 
binding agents, including cyanovirin-N and griffithsin, also target gp120 glycans and 513 
have potent antiviral activity (6). However, those proteins were originated from 514 
bacteria or plants. Whether they can be used prophylactically or therapeutically 515 
requires further evaluation. Given that the soluble forms of CD4 and DC-SIGN occur 516 
normally in vivo and that the Gly4Ser repeat liker is poorly immunogenic (43, 44), 517 
further improvement of CLDs may render their potential to be used as prophylaxis or 518 
therapeutics.  519 
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 520 
Beyond a novel antiretroviral proof-of-concept, CLDs designed in the current study 521 
may have additional potential. CD4 engagement to gp120 induces the exposures of 522 
immunogenic epitopes, including V3 and chemokine receptor binding sites. 523 
Immunization with CD4-gp120 complex has been shown to enhance viremia control 524 
in nonhuman primates (12, 15). In those studies, immunogens were crosslinked CD4-525 
gp120 complexes or recombinant fusion proteins of CD4 and gp120, in which the 526 
native epitopes on gp120 might be affected. In contrast, CLDs, especially C35NDs60c, 527 
have a lower off rate than sCD4, facilitating the formation of a more stable CD4-528 
gp120 complex, probably induced by DC-SIGN engagement. Given that DC-SIGN 529 
binding to HIV-1 gp120 increases exposure of the CD4 binding site (25), it will be 530 
interesting to determine in future studies whether CLD-bound gp120/gp140 531 
complexes can be used as immunogenic components to elicit better neutralizing 532 
antibodies. 533 
 534 
Despite the described favorable characteristics of CLDs, further improvements in 535 
antiviral activity are needed. As both CD4 and DC-SIGN components used to make 536 
CLDs do not contain glycans, we used a bacterial expression system to produce 537 
proteins. Due to the poor solubility, the target proteins were expressed mainly in the 538 
form of inclusion bodies. Even though purified target proteins showed high anti-HIV 539 
activity after refolding, a certain degree of incorrect formation of disulfide bonds 540 
or/and aggregation occurred, and this could affect their bioactivity. While careful 541 
refolding technology could decrease such wrong disulfide bonds and aggregation, this 542 
process would be difficult to scale up. Other expression systems, such as transgenic 543 
plants (50), may provide an alternative to produce proteins in a larger scale.  544 
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 545 
In conclusion, this is the first time that sDC-SIGN-based bifunctional proteins have 546 
demonstrated anti-HIV potency. The designed and expressed CLDs are novel 547 
bifunctional proteins with increased gp120 binding avidity.  CLDs inhibit HIV-1 548 
infection and dissemination in cell lines, primary dendritic cells and mucosal cervical 549 
tissues.   550 
551 
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Table 1. Kinetic parameters of gp140-CLD binding 744 
 C35NDs60c C35ND C35D C15D sCD4a sDC-SIGNb 
KD1   (M) 3.20E-10 1.66E-09 1.04E-09 2.62E-08 1.21E-09 1.43E-08 
KD2   (M) 1.17E-09 2.11E-10 5.96E-10 1.95E-09   
Ka1  (1/Ms) 9.05E+04 1.41E+04 1.41E+04 1.09E+04 5.16E+04 1.57E+04 
Ka2  (1/Ms) 1.12E+04 8.28E+04 6.99E+04 1.10E+04   
Kdis1  (1/s) 2.90E-05 2.34E-05 1.46E-05 2.86E-04 6.25E-05 2.24E-04 
Kdis2  (1/s) 1.31E-05 1.75E-05 4.17E-05 2.14E-05   
χ2langmuir 12.52  5.39  5.51  4.08  0.49  0.05  
χ2bivalent 0.38  0.10  0.59  0.91  0.90  0.52  
 745 
KD: Equilibrium (affinity) constant 746 
Ka: Association rate constant 747 
Kd: Dissociation rate constant 748 
a: the N terminal 183 aa of CD4 749 
b: the carbohydrate-recognition domain of DC-SIGN 750 
Data are representative of three independent experiments. 751 
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Table 2. Anti-HIV activity of variant CLD forms 752 
  sCD4e C15D C20D C25D C35D C25ND C35ND C35NDs60c 
HIV-1BaLa IC90 c 148.1 ± 10.4 335.7 ± 53.2 ND ND ND ND ND ND 
IC50 c 27.1 ± 3.6 60.5 ± 12.9 ND ND ND ND ND ND 
HIV-1RFa IC90 c 199.8 ± 7.2 384.2 ± 44.6 ND ND ND ND ND ND 
IC50 c 34.5 ± 2.2 77.8 ± 15.4 ND ND ND ND ND ND 
BaLb IC90 c 153.9 ± 4.3 355.2 ± 30.4 308.2 ± 30.7 126.6 ± 25.3 79.6 ± 25.1 30.7 ± 3.6 26.7 ± 2.0  28.1 ± 1.3 
     (1.9 ↓) (5.0 ↓) (5.8 ↓) (5.5 ↓) 
IC50 c 25.3 ± 1.8 66.9 ± 5.2 55.9 ± 7.3 26.4 ± 4.9 15.7 ± 4.7  4.9 ± 1.0 5.3 ± 0.5 3.3 ±  0.3 
     (1.6 ↓) (5.2 ↓) (4.8 ↓) (7.7 ↓) 
MSW2b IC90 c >1000 d ND ND ND ND 977.1 ± 77.6 990.7 ± 85.2 65.6 ± 13.5 
        (>15.2↓) 
IC50 c >1000 d ND ND ND ND 578.6 ± 53.1  667.3 ± 98.3 13.0 ± 3.7 
      (>1.7 ↓) (>1.5 ↓) (>76.9 ↓) 
CH811b IC90 c >1000 d ND ND ND ND 423.5 ± 47.6 354.7 ± 60.4 36.0 ± 3.5 
      (>2.4 ↓) (>2.8 ↓) (>27.8 ↓) 
IC50c 277.8 ± 69.1 ND ND ND ND 56.7 ± 12.9 42.8 ± 17.6 4.7 ± 0.6 
      (4.9 ↓) (6.5 ↓) (59.1 ↓) 
CC50c,d >1600 >1600 >1600 >1600 >1600 >1600 >1600 >1600 
 753 
Bold data imply that CLDs had significantly increased anti-HIV-1 activity 754 
IC50: 50% inhibitory concentration; IC90: 90% inhibitory concentration; CC50:  50% cytotoxicity concentration. All protein molar concentrations were calculated 755 
based on monomer.  756 
a; Replication competent HIV-1 757 
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b: Env-pseudotyped HIV-1 758 
c: nM 759 
d: highest concentration tested 760 
e: the N terminal 183 aa of CD4 761 
ND: not determined 762 
Data are mean ± SD of at least three independent experiments (↓ fold decrease), with each condition performed in triplicate. 763 
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Fig. 1. Schematic diagrams of CLD-expressing plasmids and biochemical 764 
characterization of purified fusion proteins  765 
(a) Schematic representation of fusion proteins. Abbrevations: sCD4, the N terminal 766 
183 aa of CD4; mC, the N terminal 106 aa of CD4; sC, the N terminal 87 aa of CD4; 767 
N, DC-SIGN neck domain; sDC-SIGN, DC-SIGN carbohydrate-recognition domain 768 
(CRD); 15, 20, 25, 35, the number of amino acids; s60c, a Cys to Ser mutation at aa 769 
60 on CD4.  (b) Schematics of CLD-expressing plasmids. All CD4 and DC-SIGN 770 
moieties for CLDs were cloned into pET-28a(+) using restriction enzyme sites Nde I, 771 
BamH I and Hind III. Restriction enzyme sites and linker sequences were introduced 772 
into CD4 and DC-SIGN sequences by PCR. (c) SDS-PAGE and western blot analysis 773 
of C35NDs60c. Purified C35NDs60c was resolved in 12% SDS-PAGE in reducing or 774 
non-reducing condition, followed by detection with Coomassie Blue staining or 775 
western blotting (reducing condition only). Lane1: western blotting analysis. 776 
C35NDs60c was detected by mAb 507 against DC-SIGN, followed by an HRP-777 
conjugated secondery antibody; lane2 and lane3: Coomassie Blue staining of 778 
C35NDs60c in reducing and non-reducing conditions, respectively; lane4: molecular 779 
marker in reducing condition. (d) Analytical ultracentrifugation in sedimentation 780 
velocity mode. CD4, peaks at 1.9S and 3.8S, corresponding to apparent moleuclar 781 
mass 21.5KD and 57.4KD; DC-SIGN, peaks at 2.0S, corresponding to apparent 782 
moleuclar mass 22.4KD; C35NDs60c, peak at 6.3S and 9.2S, corresponding to 783 
apparent moleuclar mass 214.8KD and 398.2KD. One out of three independent 784 
experiments is shown.  785 
 786 
Fig. 2. CLDs inhibit HIV-1 capture and transfer by Raji/DC-SIGN cells and 787 
iMMDCs. BaL Env-pseudotyed HIV-1 was pre-incubated with or without inhibitor 788 
for 1 h at 37°C before the addition to Raji/DC-SIGN cells or iMMDCs.  Cells pre-789 
 o
n
 M
ay 24, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  35
treated  with or without mannan were exposed to viruses as controls. After exposure 790 
to virues for 2 h at 37°C, cells were extensively washed and either lysed for capture 791 
assay or cocultured with U87-CD4.CCR5 cells for transfer assay. (a) HIV-1 captured 792 
by Raji/DC-SIGN cells. Medium alone was defined as 100% and its p24 793 
concentration was 1.79 ng/ml.  (b) RLU of HIV-1 trans-infection from Raji/DC-SIGN 794 
cells to U87-CD4.CCR5 cells. Medium alone was defined as 100%. (c) HIV-1 795 
captured by iMDDCs. Medium alone was defined as 100% and its p24 concentration 796 
was 2.87 ng/ml. (d) RLU of HIV-1 trans-infection from iMDDCs to U87-CD4.CCR5 797 
cells. Medium alone was defined as 100%. Data shown are mean ± SD of three 798 
independent experiments, with each condition performed in triplicate. 799 
 800 
Fig. 3. CLD inhibits localized mucosal HIV-1 infection and dissemination. Human 801 
cervical explants were pre-incubated with or withour inhibitors for 1 h at 37°C before 802 
exposure to HIV-1BaL for 2 h at 37°C. After incubation, explants were extensively 803 
washed and cultured in the presence of 100 ng/ml of MIP-3β for 48 h. Emigrating 804 
cells were collected, washed, and cocultured with PM1 cells. The explants were 805 
cultured in separate wells. Data are representative of three independent experiments, 806 
with each condition performed in triplicate. Data  shown are p24 antigen (mean± SD) 807 
released from both (a) cultured explants and (b) PM1 cocultured migratory cells at 808 
day 9. p24 in the absence of inhibitor was defined as 100%, and was 1.56 and 2.74 809 
ng/ml for the cervical explants and PM1 cocultured migratory cells, respectively. 810 
Anti-CD4: RPA-T4. Anti-DC-SIGN: 507+ 526. 811 
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